Loading clinical trials...
Loading clinical trials...
To development of clinical assessment technique using multi-radiotracer positron emission tomography/magnetic resonance (PET/MR) in prostate cancer * to establish the optimal imaging technique of PET/MR using multiple radioactive tracers for prostate cancer * to establish the imaging biomarker using PET/MR for clinical assessment of prostate cancer and early detection of recurrent prostate cancer
To establish the optimal imaging technique of PET/MR using multiple radioactive tracers for prostate cancer * Recruiting 30 patients with prostate cancer ahead to radical prostatectomy * PET/MR using 18F-choline with dedicated prostate MRI in all patients * PET/MR using 18fluoride(F)-fluorodeoxyglucose(FDG)in all patients after 2-7 days * PET/CT using 18F-FDG in all patient immediate after 18F-FDG PET/MR * outcome assessment: comparison of scan time, image quality, tumor detection rate, standardized uptake values of lesions * establishing optimal imaging technique for prostate PET/MR To establish the imaging biomarker using PET/MR for clinical assessment of prostate cancer * comparison of findings on PET/MR, MRI and PET/CT with pathological mapping after radical prostatectomy * outcome assessment: accuracy of PET/MR for localization and staging of prostate cancer compared with MRI only and PET/CT only To establish the imaging biomarker using PET/MR for early detection of recurrent prostate cancer * Recruiting 15 patients with recurrent prostate cancer treated by surgery, hormone, or radiation therapy * Recruiting 15 patients with treated prostate cancer without recurrence * PET/MR using 18F-choline with dedicated prostate MRI in all patients * PET/MR using 18F-FDG in all patients after 2-7 days * PET/CT using 18F-FDG in all patient immediate after 18F-FDG PET/MR * comparison of findings on PET/MR, MRI, and PET/CT with clinical data in two patient groups with or without recurrent prostate cancer * outcome assessment: accuracy of PET/MR for early detection and localization of recurrent prostate cancer compared with MRI only and PET/CT only
Age
All ages
Sex
MALE
Healthy Volunteers
No
Seoul National University Hospital
Seoul, South Korea
Start Date
May 1, 2012
Primary Completion Date
April 1, 2014
Completion Date
December 1, 2014
Last Updated
December 5, 2013
60
ESTIMATED participants
PET/MR
DEVICE
Lead Sponsor
Seoul National University Hospital
NCT05036226
NCT06508567
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05022914